Illustration — photo to followLot AV-SEM-2609-A
Semaglutide
Peptide pen · 10 mg / 3 mL
VAT included · 1 pen · 10 mg / 3 mL
Sold for research use only. Not a medicine and not authorised for human consumption. Purchasers must be 18+ and confirm intended use at checkout.
Authorised as a medicine elsewhere (United Kingdom, United States, European Union, Australia and Canada) — this pen is a research product, not the licensed medicine.
- Ships chilled · same-day dispatch before 2 pm
- Free UK shipping over £300
About
What this is
Semaglutide is included in the guide under metabolic & weight. The reference focuses on glp-1 signalling, appetite and metabolic outcomes and distinguishes biological rationale from demonstrated outcomes. Supplied by the manufacturer as a pre-filled 10 mg / 3 mL dose-dial pen for research use — no reconstitution, no vials, no drawing up. Our evidence record is linked below and graded on the same scale as every compound on this site.
- 01Pre-filled pen — no reconstitution
- 02Identity confirmed by LC-MS per lot
- 03Purity ≥ 99% by HPLC
- 04Certificate published against the lot number
Specification
What's in the pen
Device
How the pen works
- 01
Attach a pen needle
Take the cap off, wipe the septum with an alcohol swab and screw a compatible pen needle on until it seats. Use a fresh needle every time and never share a pen.
- 02
Prime
Dial a small test amount, hold the pen needle-up and press the button until a drop appears at the tip. This clears air from the needle and confirms the pen delivers.
- 03
Dial
Turn the dial to the volume you intend to deliver; the window shows the setting in the pen's increments. The dial sets a volume of solution — nothing more.
- 04
Inject
Insert as the pen-needle instructions describe, press the button fully and hold for ten seconds before withdrawing. Remove and bin the needle in a sharps container, recap and refrigerate.
Dosing is not provided; see the research information in the evidence record. These steps describe how the device operates, not how or whether to use its contents.
Certificate of analysis
Lot AV-SEM-2609-A
Independent test of a sample from lot AV-SEM-2609-A of Semaglutide. Testing confirms what is in the pen and how pure it is; it does not speak to safety or effect in people. How we test
Evidence record · reviewed 1 Sept 2026
What the research says about Semaglutide
Once-weekly incretin medicine with the largest weight-management evidence base.
- Overall evidence
- Strong
- Human evidence
- Approved medicine (for specific indications)
- Regulatory · jurisdictions on record
- Authorised
- Authorised · United Kingdom, United States, European Union, Australia and Canada
- United Kingdom · Authorised (MHRA) for type 2 diabetes and weight management; prescription-only. · reviewed 1 Sept 2026
- Anti-doping · WADA
- Not on the Prohibited List
Fit
Who this is for
Weight management with the largest human evidence base of any compound in the range.
- Significant weight to lose
- Appetite that undermines every plan
- Wanting the compound with the most trial participants
Check your fit
The Peptide Checkup maps your goal and history against the evidence for this pen and tells you if it is a poor fit — even after you have bought it.
Check your fit · 7 minutesAlso in the range · by shared goal, then bestsellers
5 related pens
- Illustration — photo to follow
Tirzepatide
Peptide pen · 30 mg / 3 mL
£320 
Tesamorelin
Peptide pen · 20 mg / 3 mL
£255
Retatrutide (R3T)
Peptide pen · 40 mg / 3 mL
£370- Illustration — photo to follow
CagriSema
Cagrilintide + semaglutide · 20 mg / 3 mL
£360 - Illustration — photo to follow
Liraglutide
Peptide pen · 18 mg / 3 mL
£235